Literature DB >> 11487421

Attrition prevention with individuals awaiting publicly funded drug treatment.

D M Donovan1, D B Rosengren, L Downey, G B Cox, K L Sloan.   

Abstract

AIMS: To evaluate the effectiveness of a motivational intervention to reduce attrition from a waiting list for substance abusers seeking publicly funded treatment.
DESIGN: Randomized clinical trial comparing an "attrition prevention" condition to standard care while awaiting treatment admission.
SETTING: A centralized substance abuse assessment and referral center in Seattle, Washington. PARTICIPANTS: Substance abusers (n = 654) eligible for publicly funded drug abuse treatment. MEASUREMENTS: Alcohol and drug use, substance-related negative consequences, areas in need of help, perceived need for help, emotional status, readiness to change, reasons for seeking and perceived barriers to entering treatment.
FINDINGS: Overall, approximately 70% of clients entered treatment, and of these approximately 70% completed their assigned treatment. Those who entered treatment showed significant reductions in substance use and improved psychosocial function at a short-term 3-month follow-up. However, the attrition prevention intervention had no differential effect on treatment entry, completion or outcome compared to the standard waiting list. Further, there were no differences across therapists on these outcome measures.
CONCLUSIONS: A motivational attrition prevention intervention did not enhance treatment entry, completion or outcome among treatment-seeking substance abusers. It is suggested that alternative strategies, such as contingency management and case management, may help facilitate treatment entry for individuals seeking publicly funded treatment.

Entities:  

Mesh:

Year:  2001        PMID: 11487421     DOI: 10.1046/j.1360-0443.2001.96811498.x

Source DB:  PubMed          Journal:  Addiction        ISSN: 0965-2140            Impact factor:   6.526


  35 in total

1.  A replicable model for achieving over 90% follow-up rates in longitudinal studies of substance abusers.

Authors:  Christy K Scott
Journal:  Drug Alcohol Depend       Date:  2004-04-09       Impact factor: 4.492

2.  Gaps in the Substance Use Disorder Treatment Referral Process: Provider Perceptions.

Authors:  Claire E Blevins; Nishi Rawat; Michael D Stein
Journal:  J Addict Med       Date:  2018 Jul/Aug       Impact factor: 3.702

Review 3.  Recent advances in the psychotherapy of addictive disorders.

Authors:  Kathleen M Carroll
Journal:  Curr Psychiatry Rep       Date:  2005-10       Impact factor: 5.285

4.  Individual and system influences on waiting time for substance abuse treatment.

Authors:  Carey J A Carr; Jiangmin Xu; Cristina Redko; D Timothy Lane; Richard C Rapp; John Goris; Robert G Carlson
Journal:  J Subst Abuse Treat       Date:  2007-05-23

5.  Improving linkage with substance abuse treatment using brief case management and motivational interviewing.

Authors:  Richard C Rapp; Amy L Otto; D Timothy Lane; Cristina Redko; Sue McGatha; Robert G Carlson
Journal:  Drug Alcohol Depend       Date:  2008-02-01       Impact factor: 4.492

6.  Interim treatment: Bridging delays to opioid treatment access.

Authors:  Stacey C Sigmon
Journal:  Prev Med       Date:  2015-04-30       Impact factor: 4.018

7.  Waiting Time as a Barrier to Treatment Entry: Perceptions of Substance Users.

Authors:  Cristina Redko; Richard C Rapp; Robert G Carlson
Journal:  J Drug Issues       Date:  2006-09

8.  Treatment entry barriers among California's Proposition 36 offenders.

Authors:  Elizabeth Evans; Libo Li; Yih-Ing Hser
Journal:  J Subst Abuse Treat       Date:  2008-06-02

9.  Implementations of a text-message intervention to increase linkage from the emergency department to outpatient treatment for substance use disorders.

Authors:  Julie Kmiec; Brian Suffoletto
Journal:  J Subst Abuse Treat       Date:  2019-02-21

10.  Challenges in motivating treatment enrollment in community syringe exchange participants.

Authors:  Michael Kidorf; Elizabeth Disney; Van King; Ken Kolodner; Peter Beilenson; Robert K Brooner
Journal:  J Urban Health       Date:  2005-07-13       Impact factor: 3.671

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.